US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
US4452773A
(en)
|
1982-04-05 |
1984-06-05 |
Canadian Patents And Development Limited |
Magnetic iron-dextran microspheres
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
JP2624470B2
(ja)
|
1984-10-02 |
1997-06-25 |
バイオジェン インコーポレイテッド |
ストレプトアビジン様ポリペプチドの製造
|
US5019369A
(en)
|
1984-10-22 |
1991-05-28 |
Vestar, Inc. |
Method of targeting tumors in humans
|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
US4795698A
(en)
|
1985-10-04 |
1989-01-03 |
Immunicon Corporation |
Magnetic-polymer particles
|
US4880935A
(en)
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
IN165717B
(fr)
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
US4851341A
(en)
|
1986-12-19 |
1989-07-25 |
Immunex Corporation |
Immunoaffinity purification system
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US5219740A
(en)
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
ES2067018T3
(es)
|
1988-12-28 |
1995-03-16 |
Stefan Miltenyi |
Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos.
|
US5200084A
(en)
|
1990-09-26 |
1993-04-06 |
Immunicon Corporation |
Apparatus and methods for magnetic separation
|
WO1992008796A1
(fr)
|
1990-11-13 |
1992-05-29 |
Immunex Corporation |
Genes de fusion selectionnables bifonctionnels
|
LU91067I2
(fr)
|
1991-06-14 |
2004-04-02 |
Genentech Inc |
Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
|
DE4228458A1
(de)
|
1992-08-27 |
1994-06-01 |
Beiersdorf Ag |
Multicistronische Expressionseinheiten und deren Verwendung
|
DE4237113B4
(de)
|
1992-11-03 |
2006-10-12 |
"Iba Gmbh" |
Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
JPH09500783A
(ja)
|
1993-05-21 |
1997-01-28 |
ターゲッティッド ジェネティクス コーポレイション |
シトシンデアミナーゼ(cd)遺伝子に基づく二機能性選択融合遺伝子
|
US5827642A
(en)
|
1994-08-31 |
1998-10-27 |
Fred Hutchinson Cancer Research Center |
Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
|
WO1996013593A2
(fr)
|
1994-10-26 |
1996-05-09 |
Procept, Inc. |
Recepteurs de lymphocites t monocatenaires solubles
|
WO1996018105A1
(fr)
|
1994-12-06 |
1996-06-13 |
The President And Fellows Of Harvard College |
Recepteur de lymphocyte t monocatenaire
|
EP0815121A4
(fr)
|
1995-02-09 |
1999-09-01 |
Univ Washington |
Streptavidine a affinite modifiee
|
EP0856055A1
(fr)
|
1995-04-11 |
1998-08-05 |
Trustees Of Boston University |
Proteines mutantes de streptavidine
|
US20020150914A1
(en)
|
1995-06-30 |
2002-10-17 |
Kobenhavns Universitet |
Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
|
DE19608753C1
(de)
|
1996-03-06 |
1997-06-26 |
Medigene Gmbh |
Transduktionssystem und seine Verwendung
|
US6451995B1
(en)
|
1996-03-20 |
2002-09-17 |
Sloan-Kettering Institute For Cancer Research |
Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
|
US7381407B1
(en)
|
1996-03-25 |
2008-06-03 |
Medarex, Inc. |
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
|
DE19641876B4
(de)
|
1996-10-10 |
2011-09-29 |
Iba Gmbh |
Streptavidinmuteine
|
WO1998040396A1
(fr)
|
1997-03-14 |
1998-09-17 |
Trustees Of Boston University |
Streptavidine a aromes multiples
|
KR100712256B1
(ko)
|
1997-10-02 |
2007-04-27 |
알토 바이오사이언스 코포레이션 |
가용성 단일쇄 t-세포 수용체 단백질
|
US5985658A
(en)
|
1997-11-14 |
1999-11-16 |
Health Research Incorporated |
Calmodulin-based cell separation technique
|
RU2149023C1
(ru)
|
1998-04-20 |
2000-05-20 |
Ерхов Валентин Сергеевич |
Способ получения специфической антисыворотки к универсальному опухолевому антигену и способ диагностики злокачественных опухолей с использованием этой антисыворотки
|
EA200001216A1
(ru)
|
1998-05-19 |
2001-06-25 |
Авидекс Лимитед |
Растворимый т-лимфоцитный рецептор
|
EP1520588B1
(fr)
|
1998-07-13 |
2014-12-24 |
Board Of Regents, The University Of Texas System |
L'utilisation d'anticorps vis-a-vis des aminophospholipides pour le traitement du cancer
|
US6406693B1
(en)
|
1998-07-13 |
2002-06-18 |
Board Of Regents, The University Of Texas System |
Cancer treatment methods using antibodies to aminophospholipids
|
WO2000014257A1
(fr)
|
1998-09-04 |
2000-03-16 |
Sloan-Kettering Institute For Cancer Research |
Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations
|
US6572856B1
(en)
|
1998-09-10 |
2003-06-03 |
The University Of Virginia Patent Foundation |
Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
|
WO2000023573A2
(fr)
|
1998-10-20 |
2000-04-27 |
City Of Hope |
Cellules modifiees specifiques a la molecule cd20 et utilisation de ces dernieres pour l'immunotherapie cellulaires des malignites cd20?+¿
|
US20040191260A1
(en)
|
2003-03-26 |
2004-09-30 |
Technion Research & Development Foundation Ltd. |
Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
|
US20020131960A1
(en)
|
2000-06-02 |
2002-09-19 |
Michel Sadelain |
Artificial antigen presenting cells and methods of use thereof
|
DE60107022T2
(de)
|
2000-07-24 |
2005-11-24 |
Health Research Inc. |
Verfahren zur Detektion von Prostata-spezifischem Membran-Antigen in Serum
|
US6379550B1
(en)
|
2000-07-24 |
2002-04-30 |
Health Research, Inc. |
Method for detecting PSA and its molecular forms using thiophilic gel
|
WO2002077029A2
(fr)
|
2000-11-07 |
2002-10-03 |
City Of Hope |
Cellules immunitaires specifiques a cd19 redirigees
|
EP1227321A1
(fr)
|
2000-12-28 |
2002-07-31 |
Institut für Bioanalytik GmbH |
Purification fonctionelle de lymphocytes T antigène-spécifiques par marquage réversible aux multimères MHC
|
WO2002062850A2
(fr)
|
2001-02-02 |
2002-08-15 |
Millennium Pharmaceuticals, Inc. |
Anticorps hybrides et leurs utilisations
|
DE10113776B4
(de)
|
2001-03-21 |
2012-08-09 |
"Iba Gmbh" |
Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
US20030007974A1
(en)
|
2001-05-30 |
2003-01-09 |
Nanus David M. |
Endopeptidase/anti-PSMA antibody fusion proteins for treatment of cancer
|
US7514078B2
(en)
|
2001-06-01 |
2009-04-07 |
Cornell Research Foundation, Inc. |
Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
|
US7666414B2
(en)
|
2001-06-01 |
2010-02-23 |
Cornell Research Foundation, Inc. |
Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
|
IL160359A0
(en)
|
2001-08-31 |
2004-07-25 |
Avidex Ltd |
Soluble t cell receptor
|
US20040161776A1
(en)
|
2001-10-23 |
2004-08-19 |
Maddon Paul J. |
PSMA formulations and uses thereof
|
US20050215472A1
(en)
|
2001-10-23 |
2005-09-29 |
Psma Development Company, Llc |
PSMA formulations and uses thereof
|
ES2606537T3
(es)
|
2001-10-23 |
2017-03-24 |
Psma Development Company L.L.C. |
Anticuerpos contra PSMA
|
US7939059B2
(en)
|
2001-12-10 |
2011-05-10 |
California Institute Of Technology |
Method for the generation of antigen-specific lymphocytes
|
US6992176B2
(en)
|
2002-02-13 |
2006-01-31 |
Technion Research & Development Foundation Ltd. |
Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
|
US20030223994A1
(en)
|
2002-02-20 |
2003-12-04 |
Hoogenboom Henricus Renerus Jacobus Mattheus |
MHC-peptide complex binding ligands
|
US20030170238A1
(en)
|
2002-03-07 |
2003-09-11 |
Gruenberg Micheal L. |
Re-activated T-cells for adoptive immunotherapy
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
JP4436319B2
(ja)
|
2002-10-09 |
2010-03-24 |
メディジーン リミテッド |
単鎖組換えt細胞レセプター
|
US20040136998A1
(en)
|
2002-10-30 |
2004-07-15 |
Bander Neil H. |
Methods and compositions for treating or preventing insulin-related disorders using binding agents specific for prostate specific membrane antigen
|
WO2004063701A2
(fr)
|
2003-01-10 |
2004-07-29 |
Millennium Pharmaceuticals, Inc. |
Procedes de diagnostic et de traitement du cancer
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
US20050202020A1
(en)
|
2004-01-09 |
2005-09-15 |
Jeffrey Ross |
Diagnosing and treating cancer
|
US20110020273A1
(en)
|
2005-04-06 |
2011-01-27 |
Ibc Pharmaceuticals, Inc. |
Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof
|
EP1610818A4
(fr)
|
2004-03-03 |
2007-09-19 |
Millennium Pharm Inc |
Anticorps modifies diriges contre un antigene membranaire specifique de la prostate
|
US20090304679A1
(en)
|
2004-05-27 |
2009-12-10 |
Weidanz Jon A |
Antibodies as T cell receptor mimics, methods of production and uses thereof
|
CA2567814C
(fr)
|
2004-05-27 |
2013-07-23 |
Jon A. Weidanz |
Anticorps mimetiques de recepteurs de cellules t et leurs procedes de production et d'utilisation
|
US20090226474A1
(en)
|
2004-05-27 |
2009-09-10 |
Weidanz Jon A |
Antibodies as T cell receptor mimics, methods of production and uses thereof
|
WO2006000830A2
(fr)
|
2004-06-29 |
2006-01-05 |
Avidex Ltd |
Substances
|
AU2006204913A1
(en)
|
2005-01-14 |
2006-07-20 |
Cytogen Corporation |
Combination cancer therapy with anti-PSMA antibodies
|
EP3698807A1
(fr)
|
2005-01-21 |
2020-08-26 |
Genentech, Inc. |
Dosage fixe d'anticorps anti-her
|
WO2006078892A2
(fr)
|
2005-01-21 |
2006-07-27 |
The Regents Of The University Of California |
Utilisation d'un nouvel antigene membranaire specifique de la prostate pour le diagnostic et le traitement du cancer
|
AU2006235421A1
(en)
|
2005-04-08 |
2006-10-19 |
Cytogen Corporation |
Conjugated anti-PSMA antibodies
|
WO2007002222A2
(fr)
|
2005-06-20 |
2007-01-04 |
Psma Development Company, Llc |
Conjugues anticorps psma-medicament
|
JP2009500346A
(ja)
|
2005-06-29 |
2009-01-08 |
ユニバーシティー・オブ・マイアミ |
癌処置用の抗体−免疫細胞リガンド融合タンパク質
|
EP1948688A2
(fr)
|
2005-11-14 |
2008-07-30 |
Psma Development Company, L.L.C. |
Compositions et procedes d'utilisation de dimeres psma stabilises
|
HUE038506T2
(hu)
|
2007-03-30 |
2018-10-29 |
Memorial Sloan Kettering Cancer Center |
Kostimuláló ligand konstitutív expressziója adoptív módon átvitt T-limfocitákon
|
US8229090B2
(en)
|
2007-04-17 |
2012-07-24 |
Verizon Patent And Licensing Inc. |
Voice portal communications
|
AU2015203742B2
(en)
|
2007-06-26 |
2016-12-01 |
The Johns Hopkins University |
Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
|
WO2009026660A1
(fr)
*
|
2007-08-30 |
2009-03-05 |
Walter And Eliza Hall Institute Of Medical Research |
Marqueur de cellules dendritiques et son utilisation
|
EP2433713B1
(fr)
|
2007-12-07 |
2017-07-26 |
Miltenyi Biotec GmbH |
Appareil et procédé de traitement des cellules
|
US8479118B2
(en)
|
2007-12-10 |
2013-07-02 |
Microsoft Corporation |
Switching search providers within a browser search box
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
US20120164718A1
(en)
|
2008-05-06 |
2012-06-28 |
Innovative Micro Technology |
Removable/disposable apparatus for MEMS particle sorting device
|
JP5173594B2
(ja)
|
2008-05-27 |
2013-04-03 |
キヤノン株式会社 |
管理装置、画像形成装置及びそれらの処理方法
|
CA2769444A1
(fr)
|
2009-05-19 |
2010-11-25 |
Aic Blab Company |
Collecteur de courant composite et procedes apparentes
|
WO2010135431A2
(fr)
|
2009-05-19 |
2010-11-25 |
The Regents Of The University Of California |
Compositions, dispositifs, et procédés relatifs à l'antigène membranaire spécifique de la prostate (psma)
|
WO2011044186A1
(fr)
|
2009-10-06 |
2011-04-14 |
The Board Of Trustees Of The University Of Illinois |
Récepteurs de lymphocytes t à chaîne unique humains
|
SI2496698T1
(sl)
|
2009-11-03 |
2019-07-31 |
City Of Hope |
Skrajšan epiderimalni receptor faktorja rasti (EGFRt) za selekcijo transduciranih T celic
|
CN102753194B
(zh)
|
2009-12-02 |
2015-07-08 |
伊麦吉纳博公司 |
靶向人前列腺特异性膜抗原的j591微抗体和双抗体
|
JP5947311B2
(ja)
|
2010-12-09 |
2016-07-06 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
癌を治療するためのキメラ抗原受容体改変t細胞の使用
|
WO2012096926A2
(fr)
|
2011-01-10 |
2012-07-19 |
President And Fellows Of Harvard College |
Procédé pour administrer des agents dans des cellules à l'aide de toxines bactériennes
|
MX359513B
(es)
|
2011-03-23 |
2018-10-01 |
Hutchinson Fred Cancer Res |
Metodo y composiciones para inmunoterapia celular.
|
SG193956A1
(en)
|
2011-04-01 |
2013-11-29 |
Sloan Kettering Inst Cancer |
T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
|
US8398282B2
(en)
|
2011-05-12 |
2013-03-19 |
Delphi Technologies, Inc. |
Vehicle front lighting assembly and systems having a variable tint electrowetting element
|
CN103797028B
(zh)
|
2011-07-18 |
2017-08-25 |
Iba 股份有限公司 |
使靶细胞可逆染色的方法
|
CN107011426B
(zh)
|
2011-11-11 |
2021-05-14 |
弗雷德哈钦森癌症研究中心 |
针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
|
EP2814846B1
(fr)
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Récepteurs d'antigène chimères bispécifiques et utilisations thérapeutiques de ceux-ci
|
WO2013126726A1
(fr)
|
2012-02-22 |
2013-08-29 |
The Trustees Of The University Of Pennsylvania |
Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation
|
CN104254780B
(zh)
|
2012-02-23 |
2017-04-12 |
朱诺治疗有限公司 |
细胞和其它复杂生物材料的色谱分离
|
US20130225541A1
(en)
|
2012-02-24 |
2013-08-29 |
Cornell University |
Elevated PSMA Identifies Lethal Prostate Cancers
|
EP2819704A4
(fr)
|
2012-02-28 |
2015-10-21 |
Univ Cornell |
Psa en tant que biomarqueur pour l'activité des androgènes dans le cancer de la prostate
|
NZ702108A
(en)
|
2012-05-03 |
2016-09-30 |
Hutchinson Fred Cancer Res |
Enhanced affinity t cell receptors and methods for making the same
|
WO2014008155A1
(fr)
|
2012-07-02 |
2014-01-09 |
The General Hospital Corporation |
Diagnostic et traitement de surveillance du cancer de la prostate
|
RU2700765C2
(ru)
|
2012-08-20 |
2019-09-19 |
Фред Хатчинсон Кансэр Рисёч Сентер |
Способ и композиции для клеточной иммунотерапии
|
EP3597215A1
(fr)
|
2012-10-02 |
2020-01-22 |
Memorial Sloan-Kettering Cancer Center |
Compositions et procédés d'immunothérapie
|
EP2904012A4
(fr)
|
2012-10-05 |
2016-05-04 |
Univ Cornell |
Inhibition des androgènes, antigène membranaire spécifique de la prostate et concept de vulnérabilité conditionnellement renforcée
|
BR112015008173A2
(pt)
|
2012-10-12 |
2017-11-28 |
Adc Therapeutics Sarl |
conjugados de pirrolobenzodiazepina-anticorpo anti-psma
|
EP2906250B1
(fr)
|
2012-10-12 |
2018-05-30 |
ADC Therapeutics SA |
Conjugués pyrrolobenzodiazepine-anticorps anti-psma
|
US10065996B2
(en)
|
2012-11-16 |
2018-09-04 |
Iba Gmbh |
Streptavidin muteins and methods of using them
|
US9107960B2
(en)
|
2012-12-13 |
2015-08-18 |
Immunimedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
WO2017004144A1
(fr)
|
2015-07-01 |
2017-01-05 |
Immunomedics, Inc. |
Immunoconjugués d'anticorps sn-38 avec un lieur cl2a
|
DE112012007250T5
(de)
|
2012-12-20 |
2015-10-08 |
Mitsubishi Electric Corp. |
Fahrzeuginterne Vorrichtung und Programm
|
US9701758B2
(en)
|
2013-05-24 |
2017-07-11 |
Board Of Regents, The University Of Texas System |
Anti-CD19 scFv (FMC63) polypeptide
|
CN103333249A
(zh)
|
2013-06-14 |
2013-10-02 |
广州康合生物科技有限公司 |
一种抗前列腺特异性膜抗原(psma)的单克隆抗体及其应用
|
US9108442B2
(en)
|
2013-08-20 |
2015-08-18 |
Ricoh Company, Ltd. |
Image forming apparatus
|
EP2871189A1
(fr)
|
2013-11-07 |
2015-05-13 |
Institut Pasteur |
Anticorps TAG anti Strep monoclonaux à affinité élevée
|
CN113354744A
(zh)
|
2013-12-20 |
2021-09-07 |
弗雷德哈钦森癌症研究中心 |
带标签的嵌合效应分子及其受体
|
LT3092010T
(lt)
|
2014-01-10 |
2018-10-25 |
Synthon Biopharmaceuticals B.V. |
Metodas, skirtas gryninimui cys-sujungtų antikūno-vaisto konjugatų
|
WO2015143029A1
(fr)
|
2014-03-18 |
2015-09-24 |
The Johns Hopkins University |
Système de rapporteur génétique moléculaire à base de psma
|
US10865242B2
(en)
*
|
2014-04-10 |
2020-12-15 |
Seattle Children's Hospital |
Method and compositions for cellular immunotherapy
|
WO2015168613A2
(fr)
|
2014-05-02 |
2015-11-05 |
The Trustees Of The University Of Pennsylvania |
Compositions de récepteurs d'auto-anticorps chimériques et procédés afférents
|
LT3151865T
(lt)
|
2014-05-22 |
2021-10-25 |
Byondis B.V. |
Prijungiamų vaistų vietai specifinis konjugavimas su antikūnais ir to pasekoje gaunami avk
|
AU2015289644A1
(en)
|
2014-07-15 |
2017-02-02 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
JP6925264B2
(ja)
|
2014-08-27 |
2021-08-25 |
メモリアル スローン ケタリング キャンサー センター |
抗体、組成物および使用
|
MA41046A
(fr)
|
2014-10-10 |
2017-08-15 |
Memorial Sloan Kettering Cancer Center |
Thérapies liées au psma
|
EP3256495A4
(fr)
|
2015-02-11 |
2018-09-19 |
Aptevo Research and Development LLC |
Compositions et méthodes de polythérapie combinées à des protéines se liant à l'antigène membranaire spécifique de la prostate
|
MX2017011600A
(es)
|
2015-03-10 |
2018-06-13 |
Sorrento Therapeutics Inc |
Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata.
|
WO2016176651A2
(fr)
|
2015-04-29 |
2016-11-03 |
Fred Hutchinson Cancer Research Center |
Cellules souches/progénitrices hématopoïétiques et effectrices non t modifiées, et leurs utilisations
|
WO2016192613A1
(fr)
|
2015-06-01 |
2016-12-08 |
中山大学 |
Anticorps bivalent comportant un fragment de liaison à l'antigène à domaine unique fusionné à un fragment fab classique
|
JP2018522833A
(ja)
|
2015-06-12 |
2018-08-16 |
イミューノメディクス、インコーポレイテッドImmunomedics, Inc. |
キメラ抗原受容体(car)コンストラクト、及びcarコンストラクトを発現するt細胞(car−t)またはnk細胞(car−nk)による疾患治療
|
EP3115066A1
(fr)
*
|
2015-07-07 |
2017-01-11 |
Technische Universität München |
Nouvelles protéines de liaison spécifiques au psma
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
AU2016334623A1
(en)
|
2015-10-07 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies with tetravalency for a costimulatory TNF receptor
|
CN108697096B
(zh)
|
2016-09-02 |
2022-05-03 |
康奈尔大学 |
对icam-1特异性的i结构域嵌合抗原受体
|
CA3050085A1
(fr)
|
2017-01-20 |
2018-07-26 |
Juno Therapeutics Gmbh |
Conjugues de surface cellulaire et compositions cellulaires et methodes associees
|
KR20210057730A
(ko)
|
2018-08-09 |
2021-05-21 |
주노 쎄러퓨티크스 인코퍼레이티드 |
조작 세포 및 이의 조성물 생성 방법
|